Comparison of pretreatment of magnesium with two different doses of rocuronium in rapid sequence intubatio
- Conditions
- Health Condition 1: G588- Other specified mononeuropathies
- Registration Number
- CTRI/2022/07/043698
- Lead Sponsor
- Anaesthesiology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Patients of either gender of aged 18â??65 years with an American Society of Anesthesiologists (ASA) physical status I or II and scheduled for elective surgery lasting longer than 60 minutes.MPG I with mouth opening atleast 3cm
Age less than 18 year or more than 45 year.
History of allergy or hypersensitivity to rocuronium or MgSO4; neuromuscular disease; history of malignant hyperthermia; preoperative medications known to influence neuromuscular function (eg, certain antibiotics [aminoglycosides], anticonvulsants [phenytoin]).
ï?§Electrolyte abnormalities (eg, hypermagnesemia or hyperkalemia); hepatic dysfunction (ie, bilirubin >1.5 Ã? upper limit of normal [ULN], alanine aminotransferase [ALT] >2.5 Ã? ULN, aspartate aminotransferase [AST] >2.5 Ã? ULN); renal insufficiency (ie, creatinine >1.5 Ã? ULN, creatinine clearance <60 mL•minâ??1 1.73 mâ??2, estimated by the formula of Cockroft & Gault).
ï?§Atrioventricular heart block; patients with magnesium treatment; those with a body mass index <19 or >28 kg•mâ??2.
ï?§Pregnant or breastfeeding women; expected difficult intubation or mask ventilation
ï?§Non willing patents.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To measure the efficacy of magnesium pretreatment in reduction of onset time with two different doses of rocuronium in patients undergoing RSITimepoint: 4 weeks to 8 weeks
- Secondary Outcome Measures
Name Time Method â?¢To assess difference in intubating conditions <br/ ><br>â?¢To assess the duration of actionof intubating dose of muscle relaxant among the two different groups <br/ ><br>â?¢To assess any adverse events <br/ ><br>Timepoint: 4-48hrs